Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 M IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 3 5 M IN PLASTIC CONTAINER.
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 3.5% M IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% in Dextrose 25% is a combination of amino acids and dextrose for parenteral nutrition. Amino acids provide nitrogen and essential substrates for protein synthesis, while dextrose provides a caloric source to prevent protein catabolism. The mechanism involves infusion into the bloodstream, bypassing gastrointestinal digestion, to maintain or restore nitrogen balance and provide energy.
Aminosyn II 3.5% M is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral/enteral nutrition. The 'M' formulation includes electrolytes and trace elements. Amino acids are incorporated into endogenous proteins, serving as substrates for gluconeogenesis, oxidative metabolism, and neurotransmitter synthesis.
Intravenous infusion. Amino acid dose based on protein requirements: 0.8-1.0 g/kg/day for stable patients, up to 1.5-2.0 g/kg/day for catabolic states. Dextrose dose based on caloric needs: typically 150-300 g/day. Infuse via central line at rates not exceeding 0.5 g/kg/hour dextrose. Typical starting rate: 50-100 mL/hr, titrated based on metabolic tolerance.
Intravenous administration; typical adult dose is 1 to 2 g amino acids/kg/day, corresponding to 30 to 60 mL/kg/day of 3.5% solution; infusion rate not to exceed 0.1 g amino acids/kg/hour.
None Documented
None Documented
Amino acids have variable half-lives (minutes to hours); dextrose has a plasma half-life of ~2 hours under euglycemic conditions. Clinically, continuous infusion maintains steady state.
Variable; amino acids have short plasma half-lives (minutes to hours) due to rapid cellular uptake and metabolism; no meaningful terminal half-life for the mixture.
Renal excretion of amino acids as urea and ammonia; dextrose is metabolized to CO2 and water. Approximately 90% of infused amino nitrogen is recovered in urine as urea within 24 hours. Dextrose is completely metabolized.
100% renal; amino acids are deaminated and metabolized to urea, which is excreted renally; minimal (<1%) biliary/fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution